Clinical Outcome in Human T-Lymphotropic Virus Type 2 Carriers Following Organ Transplantation
Benito, R. (Universidad de Zaragoza) ; Gil, J. ; Sahagún, J. (Universidad de Zaragoza) ; Soriano, V.
Resumen: Background: Frequent and rapid development of myelopathy has been reported in individuals with human T-lymphotropic virus type 1 (HTLV-1) infection following solid organ transplantation. There is no information regarding HTLV-2, a closely related virus that often infects injection drug users.
Methods: This study includes a retrospective analysis of all consecutive organ transplants performed during the last 2 decades at a large reference transplantation unit in Spain. All participants were tested for anti-HTLV antibodies.
Results: A total of 2019 individuals were tested for HTLV during the study period, including 663 potential donors and 1356 recipient candidates. Twelve (0.59%) were reactive on initial HTLV serologic screening, but only 6 (all recipients) were confirmed as positive, all for HTLV-2. Two recipients underwent liver transplantation and have remained asymptomatic despite being on tacrolimus for 4 and 8 years, respectively. Likewise, the remaining 4 HTLV-2 carriers have not developed clinical complications potentially associated with HTLV-2.
Conclusions: Unlike HTLV-1 infection, HTLV-2 infection in the transplantation setting does not seem to be associated with rapid development of neurologic complications, Given the cross-seroreactivity between HTLV-1 and HTLV-2, discriminatory rapid tests are urgently needed and would reduce unnecessary organ discharge.
Idioma: Inglés
DOI: 10.1016/j.transproceed.2020.08.029
Año: 2021
Publicado en: Transplantation Proceedings 53, 2 (2021), 743-745
ISSN: 0041-1345
Factor impacto JCR: 1.014 (2021)
Categ. JCR: IMMUNOLOGY rank: 159 / 163 = 0.975 (2021) - Q4 - T3
Categ. JCR: TRANSPLANTATION rank: 24 / 26 = 0.923 (2021) - Q4 - T3
Categ. JCR: SURGERY rank: 191 / 214 = 0.893 (2021) - Q4 - T3
Factor impacto CITESCORE: 1.7 - Medicine (Q3)
Factor impacto SCIMAGO: 0.286 - Transplantation (Q3) - Surgery (Q3)
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.
Exportado de SIDERAL (2023-05-18-13:20:56)
Visitas y descargas
Methods: This study includes a retrospective analysis of all consecutive organ transplants performed during the last 2 decades at a large reference transplantation unit in Spain. All participants were tested for anti-HTLV antibodies.
Results: A total of 2019 individuals were tested for HTLV during the study period, including 663 potential donors and 1356 recipient candidates. Twelve (0.59%) were reactive on initial HTLV serologic screening, but only 6 (all recipients) were confirmed as positive, all for HTLV-2. Two recipients underwent liver transplantation and have remained asymptomatic despite being on tacrolimus for 4 and 8 years, respectively. Likewise, the remaining 4 HTLV-2 carriers have not developed clinical complications potentially associated with HTLV-2.
Conclusions: Unlike HTLV-1 infection, HTLV-2 infection in the transplantation setting does not seem to be associated with rapid development of neurologic complications, Given the cross-seroreactivity between HTLV-1 and HTLV-2, discriminatory rapid tests are urgently needed and would reduce unnecessary organ discharge.
Idioma: Inglés
DOI: 10.1016/j.transproceed.2020.08.029
Año: 2021
Publicado en: Transplantation Proceedings 53, 2 (2021), 743-745
ISSN: 0041-1345
Factor impacto JCR: 1.014 (2021)
Categ. JCR: IMMUNOLOGY rank: 159 / 163 = 0.975 (2021) - Q4 - T3
Categ. JCR: TRANSPLANTATION rank: 24 / 26 = 0.923 (2021) - Q4 - T3
Categ. JCR: SURGERY rank: 191 / 214 = 0.893 (2021) - Q4 - T3
Factor impacto CITESCORE: 1.7 - Medicine (Q3)
Factor impacto SCIMAGO: 0.286 - Transplantation (Q3) - Surgery (Q3)
Tipo y forma: Artículo (Versión definitiva)
Área (Departamento): Área Microbiología (Dpto. Microb.Ped.Radio.Sal.Pú.)
Debe reconocer adecuadamente la autoría, proporcionar un enlace a la licencia e indicar si se han realizado cambios. Puede hacerlo de cualquier manera razonable, pero no de una manera que sugiera que tiene el apoyo del licenciador o lo recibe por el uso que hace. No puede utilizar el material para una finalidad comercial. Si remezcla, transforma o crea a partir del material, no puede difundir el material modificado.Exportado de SIDERAL (2023-05-18-13:20:56)
Enlace permanente:
Visitas y descargas
Este artículo se encuentra en las siguientes colecciones:
Artículos
Registro creado el 2020-10-20, última modificación el 2023-05-19